(E)-N-hydroxy-3-(6-{(E)-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-3-oxo-1-propen-1-yl}pyridin-2-yl)acrylamide | 1123621-22-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N-hydroxy-3-(6-{(E)-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-3-oxo-1-propen-1-yl}pyridin-2-yl)acrylamide
• 英文别名: (E)-N-hydroxy-3-(6-{(E)-3-[4-(4-methyl-piperazin-1-yl-methyl)-phenyl]-3-oxo-propenyl}-pyridin-2-yl)-acrylamide；(E)-N-hydroxy-3-[6-[(E)-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-oxoprop-1-enyl]pyridin-2-yl]prop-2-enamide
• CAS: 1123621-22-6
• 化学式: C₂₃H₂₆N₄O₃
• 分子量: 406.484
• InChiKey: NSHZNBNGZXAAFX-WGDLNXRISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (E)-N-hydroxy-3-(6-{(E)-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-3-oxo-1-propen-1-yl}pyridin-2-yl)acrylamide 、 三氟乙酸 以 水 、 乙腈 为溶剂， 以14 mg的产率得到(E)-N-hydroxy-3-(6-{(E)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-3-oxo-propenyl}-pyridin-2-yl)-acrylamide tris-trifluoroacetate
  参考文献：
  名称：

  Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors

  摘要：

  The historic deacetylases (HDACs) are able to regulate gene expression, and historic deacetylase inhibitors (HDACi) emerged as a new class of agents in the treatment of cancer as well as other human disorders such as neurodegenerative diseases. In the present investigation, we report on the synthesis and biological evaluation of compounds derived from the expansion of a HDAC inhibitor scaffold having N-hydroxy-3-phenyl-2-propenamide and N-hydroxy-3-(pyridin-2-yl)-2-propenamide as core structures and containing a phenyloxopropenyl moiety, either unsubstituted or substituted by a 4-methylpiperazin-1-yl or 4-methylpiperazin-1-ylmethyl group. The compounds were evaluated for their ability to inhibit nuclear HDACs, as well as for their in vitro antiproliferative activity. Moreover, their metabolic stability in microsomes and aqueous Solubility were studied and selected compounds were further characterized by in vivo pharmacokinetic experiments. These compounds showed a remarkable stability in vivo, compared to hydroxamic acid HDAC inhibitors that have already entered clinical trials. The representative compound 30b showed in vivo antitumor activity in a human colon carcinoma xenograft model.

  DOI：

  10.1021/jm901502p
• 作为产物：
  描述：

  在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (E)-N-hydroxy-3-(6-{(E)-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]-3-oxo-1-propen-1-yl}pyridin-2-yl)acrylamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors

  摘要：

  The historic deacetylases (HDACs) are able to regulate gene expression, and historic deacetylase inhibitors (HDACi) emerged as a new class of agents in the treatment of cancer as well as other human disorders such as neurodegenerative diseases. In the present investigation, we report on the synthesis and biological evaluation of compounds derived from the expansion of a HDAC inhibitor scaffold having N-hydroxy-3-phenyl-2-propenamide and N-hydroxy-3-(pyridin-2-yl)-2-propenamide as core structures and containing a phenyloxopropenyl moiety, either unsubstituted or substituted by a 4-methylpiperazin-1-yl or 4-methylpiperazin-1-ylmethyl group. The compounds were evaluated for their ability to inhibit nuclear HDACs, as well as for their in vitro antiproliferative activity. Moreover, their metabolic stability in microsomes and aqueous Solubility were studied and selected compounds were further characterized by in vivo pharmacokinetic experiments. These compounds showed a remarkable stability in vivo, compared to hydroxamic acid HDAC inhibitors that have already entered clinical trials. The representative compound 30b showed in vivo antitumor activity in a human colon carcinoma xenograft model.

  DOI：

  10.1021/jm901502p

文献信息

• A new class of histone deacetylase inhibitors
  申请人：DAC S.r.l.

  公开号：EP2033956A1

  公开（公告）日：2009-03-11

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl, R3, R4 are, independently, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy, and R5 and R6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.

  这项发明涉及新的组蛋白去乙酰化酶抑制剂，其通式为（I），其中：Q是键，CH2，NR5或氧，X是CH或氮，Y是键，CH2，氧或NR6，Z是CH或氮，R1，R2分别是氢或C1-C6烷基，R3，R4分别是氢，卤素，C1-C6烷基，C1-C6烷氧基，C1-C6卤代烷基或C1-C6卤代烷氧基，R5和R6的进一步定义在说明书中，并且其药用盐是可以接受的。
• NEW CLASS OF HISTONE DEACETYLASE INHIBITORS
  申请人：Minucci Saverio

  公开号：US20120115867A1

  公开（公告）日：2012-05-10

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH 2 , NR 5 or oxygen, X is CH or nitrogen, Y is a bond, CH 2 , oxygen or NR 6 , Z is CH or nitrogen, R 1 , R 2 are, independently, hydrogen or C 1 -C 6 alkyl, R 3 , R 4 are, independently, hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 haloalkoxy, and R 5 and R 6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.

  本发明涉及一种新的组蛋白去乙酰化酶抑制剂，其通式为(I)，其中：Q是键，CH2，NR5或氧，X是CH或氮，Y是键，CH2，氧或NR6，Z是CH或氮，R1、R2是独立的氢或C1-C6烷基，R3、R4是独立的氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6卤代烷氧基，R5和R6的定义在说明书中进一步给出，以及其药物可接受的盐。
• CLASS OF HISTONE DEACETYLASE INHIBITORS
  申请人：Thaler Florian

  公开号：US20100305123A1

  公开（公告）日：2010-12-02

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH 2 , NR 5 or oxygen, X is CH or nitrogen, Y is a bond, CH 2 , oxygen or NR 6 , Z is CH or nitrogen, R 1 , R 2 are, independently, hydrogen or C 1 -C 6 alkyl, R 3 , R 4 are, independently, hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 haloalkoxy, and R 5 and R 6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.

  本发明涉及一种新的组蛋白去乙酰化酶抑制剂，其通式为（I），其中：Q是键，CH2，NR5或氧，X是CH或氮，Y是键，CH2，氧或NR6，Z是CH或氮，R1，R2独立地是氢或C1-C6烷基，R3，R4独立地是氢，卤素，C1-C6烷基，C1-C6烷氧基，C1-C6卤代烷基或C1-C6卤代烷氧基，R5和R6的进一步定义在规范中，并且包括其药学上可接受的盐。
• A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS
  申请人：DAC S.r.l.

  公开号：EP2197854A1

  公开（公告）日：2010-06-23
• [EN] A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS<br/>[FR] NOUVELLE CLASSE D'INHIBITEURS DE L'HISTONE DESACÉTYLASE
  申请人：DAC SRL

  公开号：WO2009027395A1

  公开（公告）日：2009-03-05

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl, R3, R4 are, independently, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy, and R5 and R6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.